News

Clinicians' expertise can help assess inconclusive findings about the benefits of blue-light filtering glasses. This enables them to offer informed guidance to patients concerned about eye strain and sleep quality.

The company noted that its Phase Ib dose-escalation clinical trial will evaluate safety, tolerability and efficacy of VG901 in patients with RP due to biallelic CNGA1 mutations.

A multicentre study demonstrates comparable results to FS-LASIK

VG901 is a gene therapy for CNGA1-associated RP.

Cultivated autologous limbal epithelial cells (CALEC) procedure shown to be safe and feasible with early positive results of restored cornea surfaces or vision gains in four patients with severe chemical burns.

Researchers have identified markers that indicate the presence of Parkinson disease in patients an average of 7 years before the disease presents clinically.

Researchers have identified markers that indicate the presence of Parkinson’s disease in patients an average of 7 years before the disease presents clinically.

The findings of this study shed new light on processes such as learning and memory but also the development of blinding conditions.

Data may inform clinical associations, mechanistic research, trial design.

The first-line treatment to avoid visual impairment for these cases is anti-vascular endothelial growth factor therapy (VEGF).

According to Regeneron, the approval was based on data in the PULSAR and PHOTON trials, in which the drug demonstrated clinically equivalent vision gains to aflibercept Injection 2 mg that were maintained with fewer injections.

According to Regeneron, the approval was based on data in the PULSAR and PHOTON trials, in which the drug demonstrated clinically equivalent vision gains to aflibercept Injection 2 mg that were maintained with fewer injections.

According to Regeneron, the approval was based on data in the PULSAR and PHOTON trials, in which the drug demonstrated clinically equivalent vision gains to aflibercept Injection 2 mg that were maintained with fewer injections.

Adverum Biotechnologies, Inc. provided an update on the company’s ongoing Phase 2 LUNA trial evaluating ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD).

Clinicians should be alert to the fact that while artificial intelligence (AI) is capable of generating ideas and references, it is crucial to thoroughly vet and fact-check any medical research content that AI produces.

Take a look at a review of the highlights and hottest stories from Ophthalmology Times during the week of August 13, 2023.

The geographic atrophy treatment was approved by the FDA in the US earlier this month.

Clinicians should be alert to the fact that while artificial intelligence (AI) is capable of generating ideas and references, it is crucial to thoroughly vet and fact-check any medical research content that AI produces.

An area that attracts tourists and Christian pilgrims from around the world, has been found to contain microsporidium, which can cause corneal infections.

According to the company, the MAA submission is based on data from the GATHER1 and GATHER2 Phase III clinical trials.

Treatment requires a systematic, multifaceted approach to improve outcomes.

Without treatment, severe visual impairment can occur; the first-line treatment for these cases is anti-vascular endothelial growth factor therapy (VEGF).

Without treatment, severe visual impairment can occur; the first-line treatment for these cases is anti-vascular endothelial growth factor therapy (VEGF).

The 2023 SOE meeting featured symposia, awards and a spotlight on young ophthalmologists

Researchers combine blue reflectance, red/green 200° ultrawidefield images

APP13007, if approved, may have an advantageous profile in dosing frequency and side effects while reducing the inflammation and pain associated with ocular surgery.